Gastrointestinal Stromal Tumors Regularly Express Synaptic Vesicle Proteins: Evidence of a Neuroendocrine Phenotype
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Identification of a Mutation in Synapsin I, a Synaptic Vesicle Protein, in a Family with Epilepsy J Med Genet: First Published As on 1 March 2004
183 SHORT REPORT Identification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy J Med Genet: first published as on 1 March 2004. Downloaded from C C Garcia, H J Blair, M Seager, A Coulthard, S Tennant, M Buddles, A Curtis, J A Goodship ............................................................................................................................... J Med Genet 2004;41:183–187. doi: 10.1136/jmg.2003.013680 hippocampal bodies are moderately atrophic but without A four generation family is described in which some men of signal intensities. normal intelligence have epilepsy and others have various III-2 is a 64 year old man who has had a cerebrovascular combinations of epilepsy, learning difficulties, macrocephaly, accident but was previously of normal intelligence. He had and aggressive behaviour. As the phenotype in this family is tonic-clonic seizures until aged 7. His head circumference is distinct from other X linked recessive disorders linkage studies normal. were carried out. Linkage analysis was done using X III-3 is a 53 year old man with a full scale IQ that has been chromosome microsatellite polymorphisms to define the formally assessed as 72 (with the recognised error in such interval containing the causative gene. Genes from within assessments this places him within the borderline to mild the region were considered possible candidates and one of learning difficulties range). His head circumference is these, SYN1, was screened for mutations by direct DNA normal. As a teenager, he showed extreme physical aggres- sequencing of amplified products. Microsatellite analysis sion (he was held in a high security psychiatric hospital showed that the region between MAOB (Xp11.3) and between the ages of 11 and 18). -
Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering After Endocytosis
Neuron Article Increased Expression of a-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis Venu M. Nemani,1 Wei Lu,2 Victoria Berge,3 Ken Nakamura,1 Bibiana Onoa,1 Michael K. Lee,4 Farrukh A. Chaudhry,3 Roger A. Nicoll,2 and Robert H. Edwards1,* 1Departments of Neurology and Physiology, Graduate Program in Neuroscience 2Department of Cellular and Molecular Pharmacology University of California, San Francisco, San Francisco, CA 94158, USA 3The Biotechnology Centre of Oslo, Centre for Molecular Biology and Neuroscience, University of Oslo, Oslo, Norway 4Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA *Correspondence: [email protected] DOI 10.1016/j.neuron.2009.12.023 SUMMARY Parkinson’s disease (PD) and Lewy body dementia (LBD) (Spill- antini et al., 1998; Dickson, 2001). Point mutations in asyn are The protein a-synuclein accumulates in the brain of also linked to an autosomal-dominant form of PD (Polymeropou- patients with sporadic Parkinson’s disease (PD), los et al., 1997; Kru¨ ger et al., 1998; Zarranz et al., 2004). Taken and increased gene dosage causes a severe, domi- together, these observations suggest a causative role for asyn nantly inherited form of PD, but we know little about in sporadic as well as inherited PD and LBD. In addition, duplica- the effects of synuclein that precede degeneration. tion and triplication of the asyn gene suffice to cause a severe, a-Synuclein localizes to the nerve terminal, but the highly penetrant form of PD (Singleton et al., 2003; Chartier- Harlin et al., 2004), and polymorphisms in regulatory elements knockout has little if any effect on synaptic transmis- of the asyn gene predispose to PD (Maraganore et al., 2006), sion. -
Limited Diagnostic Utility of Chromogranin a Measurements in Workup of Neuroendocrine Tumors
diagnostics Article Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors Jonas Baekdal 1,2,*, Jesper Krogh 1,2, Marianne Klose 1,2, Pernille Holmager 1,2, Seppo W. Langer 1,3, Peter Oturai 1,4,5, Andreas Kjaer 1,4,5 , Birgitte Federspiel 1,6, Linda Hilsted 1,7, Jens F. Rehfeld 1,7, Ulrich Knigge 1,2,8 and Mikkel Andreassen 1,2 1 ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark; [email protected] (J.K.); [email protected] (M.K.); [email protected] (P.H.); [email protected] (S.W.L.); [email protected] (P.O.); [email protected] (A.K.); [email protected] (B.F.); [email protected] (L.H.); [email protected] (J.F.R.); [email protected] (U.K.); [email protected] (M.A.) 2 Department of Endocrinology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 3 Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 4 Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Copenhagen University Hospital, 2100 Copenhagen, Denmark 5 Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark 6 Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 7 Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 8 Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark * Correspondence: [email protected]; Tel.: +45-6013-4687 Received: 11 October 2020; Accepted: 28 October 2020; Published: 29 October 2020 Abstract: Background: Plasma chromogranin A (CgA) is related to tumor burden and recommended in the follow-up of patients diagnosed with neuroendocrine tumors (NETs). -
Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver Matthew G
Published OnlineFirst January 26, 2018; DOI: 10.1158/1078-0432.CCR-17-3646 CCR Translations Clinical Cancer Research Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver Matthew G. Oser1,2 and Pasi A. Janne€ 1,2,3 Small-cell neuroendocrine cancers often originate in the lung SCCB and SCLC share common genetic driver mutations. but can also arise in the bladder or prostate. Phenotypically, Clin Cancer Res; 24(8); 1775–6. Ó2018 AACR. small-cell carcinoma of the bladder (SCCB) shares many simi- See related article by Chang et al., p. 1965 larities with small-cell lung cancer (SCLC). It is unknown whether In this issue of Clinical Cancer Research, Chang and colleagues ponent, suggesting that RB1 and TP53 loss occurs after the initial (1) perform DNA sequencing to characterize the mutational development of the urothelial carcinoma and is required for signature of small-cell carcinoma of the bladder (SCCB). They transdifferentiation from urothelial cancer to SCCB. This is rem- find that both SCCB and small-cell lung cancer (SCLC) harbor iniscent of a similar phenomenon observed in two other tumors near universal loss-of-function mutations in RB1 and TP53.In types: (i) EGFR-mutant lung cancer and (ii) castration-resistant contrast to the smoking mutational signature found in SCLC, prostate cancer, where RB1 and TP53 loss is necessary for the SCCB has an APOBEC mutational signature, a signature also transdifferentiation from an adenocarcinoma to a small-cell neu- found in urothelial carcinoma. Furthermore, they show that SCCB roendocrine tumor. EGFR-mutant lung cancers acquire RB1 loss as and urothelial carcinoma share many common mutations that are a mechanism of resistance to EGFR tyrosine kinase inhibitors (3), distinct from mutations found in SCLC, suggesting that SCCB and castration-resistant prostate cancers acquire RB1 and TP53 may arise from a preexisting urothelial cancer. -
A Novel Method of Neural Differentiation of PC12 Cells by Using Opti-MEM As a Basic Induction Medium
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 41: 195-201, 2018 A novel method of neural differentiation of PC12 cells by using Opti-MEM as a basic induction medium RENDONG HU1*, QIAOYU CAO2*, ZHONGQING SUN3, JINYING CHEN4, QING ZHENG2 and FEI XIAO1 1Department of Pharmacology, School of Medicine, Jinan University; 2College of Pharmacy, Jinan University, Guangzhou, Guangdong 510632; 3Department of Anesthesia and Intensive Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, SAR; 4Department of Ophthalmology, The First Clinical Medical College of Jinan University, Guangzhou, Guangdong 510632, P.R. China Received April 5, 2017; Accepted October 11, 2017 DOI: 10.3892/ijmm.2017.3195 Abstract. The PC12 cell line is a classical neuronal cell model Introduction due to its ability to acquire the sympathetic neurons features when deal with nerve growth factor (NGF). In the present study, The PC12 cell line is traceable to a pheochromocytoma from the authors used a variety of different methods to induce PC12 the rat adrenal medulla (1-4). When exposed to nerve growth cells, such as Opti-MEM medium containing different concen- factor (NGF), PC12 cells present an observable change in trations of fetal bovine serum (FBS) and horse serum compared sympathetic neuron phenotype and properties. Neural differ- with RPMI-1640 medium, and then observed the neurite length, entiation of PC12 has been widely used as a neuron cell model differentiation, adhesion, cell proliferation and action poten- in neuroscience, such as in the nerve injury-induced neuro- tial, as well as the protein levels of axonal growth-associated pathic pain model (5) and nitric oxide-induced neurotoxicity protein 43 (GAP-43) and synaptic protein synapsin-1, among model (6). -
Chromogranin a Regulation of Obesity and Peripheral Insulin Sensitivity
MINI REVIEW published: 08 February 2017 doi: 10.3389/fendo.2017.00020 Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity Gautam K. Bandyopadhyay1 and Sushil K. Mahata1,2* 1 Department of Medicine, University of California San Diego, La Jolla, CA, USA, 2 Department of Medicine, Metabolic Physiology and Ultrastructural Biology Laboratory, VA San Diego Healthcare System, San Diego, CA, USA Chromogranin A (CgA) is a prohormone and granulogenic factor in endocrine and neuroendocrine tissues, as well as in neurons, and has a regulated secretory pathway. The intracellular functions of CgA include the initiation and regulation of dense-core granule biogenesis and sequestration of hormones in neuroendocrine cells. This protein is co-stored and co-released with secreted hormones. The extracellular functions of CgA include the generation of bioactive peptides, such as pancreastatin (PST), vaso- statin, WE14, catestatin (CST), and serpinin. CgA knockout mice (Chga-KO) display: (i) hypertension with increased plasma catecholamines, (ii) obesity, (iii) improved hepatic Edited by: insulin sensitivity, and (iv) muscle insulin resistance. These findings suggest that individual Gaetano Santulli, CgA-derived peptides may regulate different physiological functions. Indeed, additional Columbia University, USA studies have revealed that the pro-inflammatory PST influences insulin sensitivity and Reviewed by: Anne-Francoise Burnol, glucose tolerance, whereas CST alleviates adiposity and hypertension. This review will Institut national de la santé et de la focus on the different metabolic roles of PST and CST peptides in insulin-sensitive and recherche médicale, France Marialuisa Appetecchia, insulin-resistant models, and their potential use as therapeutic targets. Istituti Fisioterapici Ospitalieri (IRCCS), Italy Keywords: obesity, insulin resistance, inflammation, chromogranin A knockout, pancreastatin, catestatin Hiroki Mizukami, Hirosaki University, Japan *Correspondence: INTRODUCTION Sushil K. -
Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened. -
Selective Lowering of Synapsins Induced by Oligomeric Α-Synuclein Exacerbates Memory Deficits
Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits Megan E. Larsona,b,c,1, Susan J. Greimela,b,c,1, Fatou Amara,b,c, Michael LaCroixa,b,c, Gabriel Boylea,b,c, Mathew A. Shermana,b,c, Hallie Schleya,b,c, Camille Miela,b,c, Julie A. Schneiderd, Rakez Kayede, Fabio Benfenatif,g, Michael K. Leea,c, David A. Bennettd, and Sylvain E. Lesnéa,b,c,2 aDepartment of Neuroscience, University of Minnesota, Minneapolis, MN 55414; bN. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55414; cInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55414; dRush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL 60612; eDepartment of Neurology, University of Texas Medical Branch, Galveston, TX 77555; fCenter for Synaptic Neuroscience, Istituto Italiano di Tecnologia, 16132 Genoa, Italy; and gDepartment of Experimental Medicine, University of Genova, 16132 Genoa, Italy Edited by Solomon H. Snyder, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved April 24, 2017 (received for review April 4, 2017) Mounting evidence indicates that soluble oligomeric forms of a reduction in the synaptic vesicle recycling pool, and a selective amyloid proteins linked to neurodegenerative disorders, such as lowering of complexins and synapsins (8). Moreover, large mul- amyloid-β (Aβ), tau, or α-synuclein (αSyn) might be the major del- timeric assemblies of recombinant αSyn were recently shown to eterious species for neuronal function in these diseases. Here, we inhibit exocytosis by preferentially binding to synaptobrevin, found an abnormal accumulation of oligomeric αSyn species in AD thereby preventing normal SNARE-mediated vesicle docking (9). -
Cardiac Arrhythmia After Myocardial Infarction
CARDIAC ARRHYTHMIA AFTER MYOCARDIAL INFARCTION: INSIGHTS FROM A DYNAMIC CANINE VENTRICULAR MYOCYTE MODEL by Thomas J. Hund Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Thesis Advisor: Dr. Yoram Rudy Department of Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY May 2004 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ______________________________________________________ candidate for the Ph.D. degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. For Keila iii TABLE OF CONTENTS List of Tables ...................................................................................................................... 3 List of Figures..................................................................................................................... 4 Acknowledgments............................................................................................................... 6 List of Abbreviations .......................................................................................................... 7 Glossary ............................................................................................................................. -
Post-Transcriptional Regulation of Synaptic Vesicle Protein Expression and the Developmental Control of Synaptic Vesicle Formation
The Journal of Neuroscience, April 1, 1997, 17(7):2365–2375 Post-Transcriptional Regulation of Synaptic Vesicle Protein Expression and the Developmental Control of Synaptic Vesicle Formation Christopher Daly and Edward B. Ziff Department of Biochemistry, Howard Hughes Medical Institute, New York University Medical Center, New York, New York 10016 The regulated expression of synaptic vesicle (SV) proteins dur- synaptophysin synthesis is not simply the result of an increase ing development and the assembly of these proteins into func- in mRNA level, but is largely attributable to an increase in the tional SVs are critical aspects of nervous system maturation. rate of translational initiation. Despite the nearly constant rates We have examined the expression patterns of four SV proteins of synthesis of synaptotagmin I, vamp 2, and synapsin I, we in embryonic hippocampal neurons developing in culture and show that the number of SVs in these developing neurons have found that increases in the levels of these proteins result increases, and that SV proteins are more efficiently targeted to primarily from post-transcriptional regulation. Synaptotagmin I, SVs at later times in culture. Our results suggest that SV vamp 2, and synapsin I proteins are synthesized at nearly production during development is not limited by the rates of constant rates as the neurons develop. However, these pro- transcription of genes encoding the component proteins, thus teins are relatively unstable at early times in culture and un- allowing control of this process by cytoplasmic mechanisms, dergo a progressive increase in half-life with time, possibly as a without signaling to the nucleus. -
Synapsin I in PC1 2 Cells. I. Characterization of the Phosphoprotein and Effect of Chronic NGF Treatment
The Journal of Neuroscience, May 1987, 7(5): 1294-l 299 Synapsin I in PC1 2 Cells. I. Characterization of the Phosphoprotein and Effect of Chronic NGF Treatment Carmelo Romano, Robert A. Nichols, Paul Greengard, and Lloyd A. Greene Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York 10021; and Department of Pharmacology, New York University School of Medicine, New York, New York 10016 PC1 2 cells contain a synapsin l-like molecule. Several serum Adrenal chromaffin cells and sympathetic neurons share a and monoclonal antibodies raised against bovine brain syn- neural crest origin and many other similarities (Coupland, 1965; apsin I bind to and precipitate this molecule, demonstrating Weston, 1970). Nevertheless, normal rat adrenal chromaffin immunochemical similarity between the brain and PC12 cells do not, whereassympathetic neurons do, contain synapsin species. PC12 synapsin I, like brain synapsin I, is a phos- I (DeCamilli et al., 1979; Fried et al., 1982). To better under- phoprotein: It is phosphorylated in intact cells and, when stand the developmental regulation of synapsin I, it was there- partially purified, serves as a substrate for several synapsin fore of interest to study synapsin I in PC 12 cells and its possible I kinases. PC1 2 cell synapsin I is structurally similar to brain alteration upon treatment of the cells with NGF. This paper synapsin I as shown by peptide mapping of %-methionine- characterizes the synapsin I present in PC12 cells and demon- and 32P-phosphate-labeled molecules from the 2 sources. strates effects of long-term NGF treatment of the cells on the Chronic NGF treatment of the cells induces a significant phosphoprotein.The accompanyingpaper (Roman0 et al., 1987) increase in the amount of synapsin I relative to total cell demonstratesthat short-term NGF treatment of PC12 cells re- protein, measured either by immunolabeling or incorporation sults in the phosphorylation of synapsin I at a novel site. -
Neurod1 Regulation of Migration Accompanies the Differential Sensitivity of Neuroendocrine Carcinomas to Trkb Inhibition
OPEN Citation: Oncogenesis (2013) 2, e63; doi:10.1038/oncsis.2013.24 & 2013 Macmillan Publishers Limited All rights reserved 2157-9024/13 www.nature.com/oncsis ORIGINAL ARTICLE NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition JK Osborne1, JE Larsen2, JX Gonzales1, DS Shames2,4, M Sato2,5, II Wistuba3, L Girard1,2, JD Minna1,2 and MH Cobb1 The developmental transcription factor NeuroD1 is anomalously expressed in a subset of aggressive neuroendocrine tumors. Previously, we demonstrated that TrkB and neural cell adhesion molecule (NCAM) are downstream targets of NeuroD1 that contribute to the actions of neurogenic differentiation 1 (NeuroD1) in neuroendocrine lung. We found that several malignant melanoma and prostate cell lines express NeuroD1 and TrkB. Inhibition of TrkB activity decreased invasion in several neuroendocrine pigmented melanoma but not in prostate cell lines. We also found that loss of the tumor suppressor p53 increased NeuroD1 expression in normal human bronchial epithelial cells and cancer cells with neuroendocrine features. Although we found that a major mechanism of action of NeuroD1 is by the regulation of TrkB, effective targeting of TrkB to inhibit invasion may depend on the cell of origin. These findings suggest that NeuroD1 is a lineage-dependent oncogene acting through its downstream target, TrkB, across multiple cancer types, which may provide new insights into the pathogenesis of neuroendocrine cancers. Oncogenesis (2013) 2, e63; doi:10.1038/oncsis.2013.24; published online 19 August 2013 Subject Categories: Cellular oncogenes Keywords: NeuroD1; neuroendocrine; TrkB; migration INTRODUCTION increased expression of NeuroD1, possibly in a lineage-dependent Aberrant expression of basic helix loop helix transcription factors manner.